The National Institute on Aging awarded local NeuroGenetic Pharmaceuticals Inc. a biopharmaceutical company focused on Alzheimer’s disease therapeutics, $2.5 million grant for its first human clinical trials on a molecule that could treat and prevent Alzheimer’s disease.

This research project grant funds pilot clinical trials for NGP 555, an amyloid modulator that shows brain penetration in pre-clinical models and is available in capsules for once daily dosing.

By combining early disease identification with a possible treatment for preventing Alzheimer’s disease-related pathology, NeuroGenetic Pharmaceuticals can prevent the formation and the deposition of amyloid plaques in the human brain, precluding neuronal cell death and dementia associated with Alzheimer’s disease.

The 14-day Phase 1b multiple ascending dose trial is expected to begin next month.